{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T04:13:39Z","timestamp":1785039219781,"version":"3.55.0"},"reference-count":96,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T00:00:00Z","timestamp":1650931200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Science Centre in Poland","award":["UMO-2017\/25\/B\/NZ3\/00251"],"award-info":[{"award-number":["UMO-2017\/25\/B\/NZ3\/00251"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Glioblastoma multiforme (GBM) is the deadliest and the most heterogeneous brain cancer. The median survival time of GBM patients is approximately 8 to 15 months after initial diagnosis. GBM development is determined by numerous signaling pathways and is considered one of the most challenging and complicated-to-treat cancer types. Standard GBM therapy consist of surgery followed by radiotherapy or chemotherapy, and combined treatment. Current standard of care (SOC) does not offer a significant chance for GBM patients to combat cancer, and the selection of available drugs is limited. For almost 20 years, there has been only one drug, Temozolomide (TMZ), approved as a first-line GBM treatment. Due to the limited efficacy of TMZ and the high rate of resistant patients, the implementation of new chemotherapeutics is highly desired. However, due to the unique properties of GBM, many challenges still need to be overcome before reaching a \u2018breakthrough\u2019. This review article describes the most recent compounds introduced into clinical trials as drug candidates for GBM chemotherapy.<\/jats:p>","DOI":"10.3390\/biomedicines10051001","type":"journal-article","created":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T11:45:55Z","timestamp":1650973555000},"page":"1001","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Looking for the Holy Grail\u2014Drug Candidates for Glioblastoma Multiforme Chemotherapy"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3565-8860","authenticated-orcid":false,"given":"Beata","family":"Paj\u0105k","sequence":"first","affiliation":[{"name":"Independent Laboratory of Genetics and Molecular Biology, Kaczkowski Military Institute of Hygiene and Epidemiology, Kozielska 4, 01-163 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,4,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1007\/s12094-016-1497-x","article-title":"Survival in glioblastoma: A review on the impact of treatment modalities","volume":"18","year":"2016","journal-title":"Clin. Transl. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/ajns.AJNS_180_20","article-title":"The impact of surgery on the survival of patients with recurrent glioblastoma","volume":"16","author":"Sacko","year":"2021","journal-title":"Asian J. Neurosur."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"CNS76","DOI":"10.2217\/cns-2021-0007","article-title":"Treatment patterns and outcomes for patients with newly diagnosed glioblastoma multiforme: A retrospective cohort study","volume":"10","author":"Annavarapau","year":"2021","journal-title":"CNS Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s11060-014-1640-x","article-title":"The relative value of postoperative versus preoperative Karnofsky Performace Scale scores as a predictor of survival after surgical resection of glioblastoma multiforme","volume":"121","author":"Chambles","year":"2015","journal-title":"J. Neurooncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jnci.2016.07.001","article-title":"Management of glioblastoma after recurrence: A changing paradigm","volume":"28","author":"Mallick","year":"2016","journal-title":"J. Egypt. Nat. Cancer Inst."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3322\/caac.21613","article-title":"Management of glioblastoma: State of the art and future directions","volume":"79","author":"Tan","year":"2020","journal-title":"Cancer J. Clin."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"6767","DOI":"10.1158\/1078-0432.CCR-05-0722","article-title":"Food and Drug Administration Drug approval summary: Temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme","volume":"11","author":"Cohen","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3389\/fphys.2018.00170","article-title":"Advances in glioblastoma multiforme treatment: New models for nanoparticle therapy","volume":"9","author":"Qutub","year":"2018","journal-title":"Front. Physiol."},{"key":"ref_9","first-page":"93","article-title":"Temozolomide: The evidence for its therapeutic efficacy in malignant astrocytomas","volume":"4","author":"Omar","year":"2009","journal-title":"Core Evid."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Barciszewska, A.M., Gurda, D., G\u0142odowicz, P., Nowak, S., and Nasket-Barciszewska, M.Z. (2015). A new epigenetic mechanism of temozolomide action in glioma cells. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0136669"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1215\/15228517-2008-090","article-title":"Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts","volume":"11","author":"Kitange","year":"2009","journal-title":"Neuro. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.gendis.2016.04.007","article-title":"Temozolomide resistance in glioblastoma multiforme","volume":"3","author":"Lee","year":"2016","journal-title":"Genes Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"897","DOI":"10.3389\/fonc.2020.00897","article-title":"A potential mechanism of temozolomide resistance in glioma\u2014Ferroptosis","volume":"10","author":"Hu","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_14","first-page":"513","article-title":"Temozolomide: An updated overview of resistance mechanisms, nanotechnology advances and clinical applications","volume":"19","author":"Ortiz","year":"2021","journal-title":"Curr. Neuropharmacol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Perazzoli, G., Prados, J., Ortiz, R., Caba, O., Cabeza, L., Berdasco, M., Gonzalez, B., and Melguizo, C. (2015). Temozolomide resistance in glioblastoma cell lines: Implication of MGMT, MMR, P-glycoprotein and CD133 expression. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0140131"},{"key":"ref_16","first-page":"17","article-title":"Mechanisms of temozolomide resistance in glioblastoma\u2014A comprehensive review","volume":"4","author":"Singh","year":"2021","journal-title":"Cancer Drug Resist."},{"key":"ref_17","first-page":"444","article-title":"Temozolomide-related hematologic toxicity","volume":"36","author":"Scaringi","year":"2013","journal-title":"Onkologie"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"163","DOI":"10.4103\/2278-330X.175953","article-title":"Recurrent glioblastoma: Where we stand","volume":"4","author":"Roy","year":"2015","journal-title":"South Asian J. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1159\/000431236","article-title":"Second-line chemotherapy in recurent glioblastoma: A 2-cohort study","volume":"38","author":"Carvalho","year":"2015","journal-title":"Oncol. Res. Treat."},{"key":"ref_20","first-page":"3","article-title":"Glioblastoma multiforme: A review of its epidemiology and pathogenesis through clinical presentation and treatment","volume":"18","author":"Hanif","year":"2017","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.3389\/fneur.2020.01036","article-title":"Carmustine as s supplementary therapeutic option for glioblastoma: A systematic review and meta-analysis","volume":"11","author":"Xiao","year":"2020","journal-title":"Front. Neurol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"S802","DOI":"10.21037\/tcr.2018.08.19","article-title":"Bevacizumab as an adjuvant therapy for glioblastoma in elderly patients: The facts","volume":"7","author":"Lyon","year":"2018","journal-title":"Transl. Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","article-title":"Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma","volume":"27","author":"Friedman","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1200\/JCO.2008.16.3055","article-title":"Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma","volume":"27","author":"Kreisl","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1056\/NEJMoa1707358","article-title":"Lomustine and bevacizumab in progressive glioblastoma","volume":"377","author":"Wick","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s00280-017-3405-7","article-title":"Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma","volume":"80","author":"Badruddoja","year":"2017","journal-title":"Cancer Chemother. Pharm."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1002\/cncr.26381","article-title":"Bevacizumab and daily temozolomide for recurrent glioblastoma","volume":"118","author":"Dasjardis","year":"2012","journal-title":"Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/annonc\/mdy106","article-title":"Bevacizumab may improve quality of life, but not overall survival in glioblastoma: An epidemiological study","volume":"29","author":"Gramatzki","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/nrc1478","article-title":"Why do cancers have high aerobic glycolysis?","volume":"4","author":"Gatenby","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1126\/science.1160809","article-title":"Understanding the Warburg effect: The metabolic requirements of cell proliferation","volume":"324","author":"Cantley","year":"2009","journal-title":"Science"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"16767","DOI":"10.1074\/jbc.M901790200","article-title":"Genome-wide Association of Hypoxia-inducible Factor (HIF)-1\u03b1 and HIF-2\u03b1 DNA Binding with Expression Profiling of Hypoxia-inducible Transcripts","volume":"284","author":"Mole","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1113\/JP280572","article-title":"Regulation of glycolysis by the hypoxia-inducible factor (HIF): Implications for cellular physiology","volume":"599","author":"Kierans","year":"2021","journal-title":"J. Physiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"436981","DOI":"10.1155\/2012\/436981","article-title":"Oxygen versus Reactive Oxygen in Regulation of HIF-1\u03b1: The balance tips","volume":"2012","author":"Hagen","year":"2012","journal-title":"Biochem. Res. Int."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Pajak, B., Siwiak, E., So\u0142tyka, M., Priebe, A., Zieli\u0144ski, R., Fokt, I., Ziemniak, M., Ja\u015bkiewicz, A., Borowski, R., and Domoradzaki, T. (2020). 2-deoxy-D-glucose and its analogs: From diagnostic to therapeutic agents. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21010234"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1203\/00006450-198404000-00011","article-title":"The 2-deoxyglucose test as a supplement to fasting for detection of childhood hypoglycemia","volume":"18","author":"Hansen","year":"1984","journal-title":"Pediatr. Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3109\/07853890.2013.785233","article-title":"Comparison of normal fsting and one-hour glucose levels as predictors of future diabetes during a 34-year follow-up","volume":"45","author":"Strandberg","year":"2013","journal-title":"Ann. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ymgme.2013.03.019","article-title":"Long-term safety of dichloroacetate in congenital lactic acidosis","volume":"109","author":"Abdelmalak","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"ref_38","first-page":"38","article-title":"Pyruvate dehydrogenase kinase as a novel therapeutic target in oncology","volume":"3","author":"Satundera","year":"2013","journal-title":"Front. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/sj.bjc.6604554","article-title":"Dichloroactetae (DCA) as a potential metabolic-targeting therapy for cancer","volume":"99","author":"Michelakis","year":"2008","journal-title":"Br. J. Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"31ra34","DOI":"10.1126\/scitranslmed.3000677","article-title":"Metabolic modulation of glioblastoma with dichloroacetate","volume":"2","author":"Michelakis","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10637-015-0221-y","article-title":"A phase I open-labeled, single-arm, dose-escalation study of dichloroacetate (DCA) in patients with advanced solid tumors","volume":"33","author":"Chu","year":"2015","journal-title":"Investig. New Drugs"},{"key":"ref_42","first-page":"21","article-title":"A novel form of dichloroactetate therapy for patients with advanced cancer: A report of 3 cases","volume":"20","author":"Khan","year":"2014","journal-title":"Altern. Health Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"8201079","DOI":"10.1155\/2019\/8201079","article-title":"Dichloroacetate (DCA) and cancer: An overview towards clinical applications","volume":"2019","author":"Tataranni","year":"2019","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"17744","DOI":"10.1038\/s41598-018-35815-4","article-title":"Dichloroacetate and salinomycin exert a synergistic cytotoxic effect in colorectal cancer cell lines","volume":"8","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/jphp.13033","article-title":"Combined use of arginase and dichloroacetate exhibits anti-proliferative effects in triple negative breast cancer cells","volume":"71","author":"Verma","year":"2019","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"51748","DOI":"10.18632\/oncotarget.18518","article-title":"Inhibition of COX2 enhances the chemosensitivity of dichloroacetate in cervical cancer cells","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Lucido, C., Miskimins, W., and Vermeer, P. (2018). Propranolol promotes glucose dependence and synergizes with dichloroacetate for anti-cancer activity in HNSCC. Cancers, 10.","DOI":"10.3390\/cancers10120476"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"205","DOI":"10.31768\/2312-8852.2018.40(3):205-210","article-title":"Influence of metformin, sodium dichloroacetate and their combination on the hematological and biochemical blood parameters of rats with gliomas C6","volume":"40","author":"Prokhorova","year":"2018","journal-title":"Exp. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"14","DOI":"10.32471\/exp-oncology.2312-8852.vol-41-no-1.12432","article-title":"Time-dependent cytotoxicity of dichloroacetate and metformin against Lewis lung carcinoma","volume":"41","author":"Kolesnik","year":"2019","journal-title":"Exp. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1007\/s10637-012-9794-x","article-title":"Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas","volume":"30","author":"Ruban","year":"2012","journal-title":"Investig. New Drugs"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"vi43","DOI":"10.1093\/neuonc\/noz175.171","article-title":"Oxaloacetate alters glucose metabolism in glioblastoma: 13C isotopomer study","volume":"21","author":"Ijare","year":"2019","journal-title":"Neuro-Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1002\/cam4.1410","article-title":"Oxaloacetate induces apoptosis in HepG2 cells via inhibition of glycolysis","volume":"7","author":"Kuang","year":"2018","journal-title":"Cancer Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1186\/s12967-015-0758-8","article-title":"Cycling hypoxia induces chemoresistance through the activation of reactive oxygen species-mediated B-cell lymphoma extra-long pathway in glioblastoma multiforme","volume":"13","author":"Chen","year":"2015","journal-title":"J. Transl. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.18632\/oncotarget.561","article-title":"Targeting HIF2\u03b1 translation with Tempol in VHL-deficient clear cell renal cell carcinoma","volume":"3","author":"Sourbier","year":"2012","journal-title":"Oncotarget"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Pajak, B., Siwiak-Niedbalska, E., Ja\u015bkiewicz, A., So\u0142tyka, M., Zieli\u0144ski, R., Domoradzki, T., Fokt, I., Sk\u00f3ra, S., and Priebe, W. (2021). Synregistic anticancer effect of glycolysis and histone deacetylases inhibitors in a glioblastoma model. Biomedicines, 9.","DOI":"10.3390\/biomedicines9121749"},{"key":"ref_56","unstructured":"(2022, March 29). Moleculin Receives FDA Allowance to Begin a Phase 1 Study of WP1122 for the Treatment of Glioblastoma Multiforme. Available online: https:\/\/www.biospace.com\/article\/releases\/moleculin-receives-fda-allowance-to-begin-a-phase-1-study-of-wp1122-for-the-treatment-of-glioblastoma-multiforme\/."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.jocn.2013.03.006","article-title":"The role of Stat3 in glioblastoma multiforme","volume":"20","author":"Luwor","year":"2013","journal-title":"J. Clin. Neurosci."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"6042","DOI":"10.1158\/1078-0432.CCR-07-4923","article-title":"Constitutively activated STAT3 frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes them to Iressa and alkylators","volume":"14","author":"Lo","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"5943","DOI":"10.7150\/thno.41498","article-title":"ACT001 reduces the expression of PD-L1 by inhibiting the phosphorylation of STAT3 in glioblastoma","volume":"10","author":"Tong","year":"2020","journal-title":"Theranostic"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2478\/v10042-008-0019-2","article-title":"Molecular basis of parthenolide-dependent proapoptotic activity in cancer cells","volume":"46","author":"Pajak","year":"2008","journal-title":"Folia Histochem. Cytobiol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1208\/pt0804105","article-title":"The solution and solid state stability and excipient compatibility of parthenolide in feverfew","volume":"8","author":"Jin","year":"2007","journal-title":"AAPS Pharm. Sci. Tech."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.drudis.2010.06.002","article-title":"What made sesquiterpene lactones reach cancer clinical trials","volume":"15","author":"Ghantous","year":"2010","journal-title":"Drug Discov. Today"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e14048","DOI":"10.1200\/JCO.2018.36.15_suppl.e14048","article-title":"Phase 1 dose-escalation study of ACT001 in patients with recurrent glioblastoma and other advanced solid tumors","volume":"36","author":"Lickliter","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"13913","DOI":"10.1021\/acsomega.9b01601","article-title":"If you cannot win them, join them: Understanding new ways to target STAT3 by small molecules","volume":"4","author":"Zariquiey","year":"2019","journal-title":"ACS Omega"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"14811","DOI":"10.1073\/pnas.1515876112","article-title":"Mutations in the linker domain affect phosho-STAT3 function and suggest targets for interrupting STAT3 activity","volume":"112","author":"Mertens","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1186\/s13046-019-1289-6","article-title":"Napabucasin, a novel STAT3 inhibitor suppresses proliferation, invasion and stemness of glioblastoma cells","volume":"38","author":"Han","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_67","unstructured":"(2022, March 27). A Study of BBI608 in Combination With Temozolomide in Adult Patients with Recurrent or Progressed Glioblastoma, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT02315534."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1038\/sj.onc.1210031","article-title":"A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo","volume":"26","author":"Iwamuru","year":"2007","journal-title":"Oncogene"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1021\/acs.molpharmaceut.9b01271","article-title":"Combating glioblastoma by codelivering the small-molecule inhibitor of STAT3 and STAT3siRNA with a5b1 integrin receptor-selective liposomes","volume":"17","author":"Vangala","year":"2020","journal-title":"Mol. Pharm."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.3389\/fonc.2020.01120","article-title":"STAT3 contributes to radioresistance in cancer","volume":"10","author":"Wang","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"4983","DOI":"10.1158\/1078-0432.CCR-19-4092","article-title":"Radiation with STAT3 blockade triggers dendritic cell-T cell interactions in the glioma microenvironment and therapeuthc efficact","volume":"26","author":"Ott","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_72","first-page":"727","article-title":"PD-1\/PD-L1 pathway: Current researchers in cancer","volume":"10","author":"Han","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Litak, J., Mazurek, M., Grochowski, C., Kamieniak, P., and Roli\u0144ski, J. (2019). PD-L1\/PD-1 axis in glioblastoma multiforme. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20215347"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.3389\/fonc.2020.01015","article-title":"PD-L1 expression in glioblastoma, the clinical and prognostic significance: A systematic literature review and meta-analysis","volume":"10","author":"Hao","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"49702","DOI":"10.18632\/oncotarget.17922","article-title":"Relationship between expression of PD-L1 and tumor angiogenesis, proliferation, and invasion in glioma","volume":"8","author":"Xue","year":"2017","journal-title":"Oncotarget"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Gottlieb, R., and Mehta, P.K. (2017). Chapter 1\u2014Current Trends in Cancer Therapy. Cardio-Oncology, Principles, Prevention and Management, Academic Press.","DOI":"10.1016\/B978-0-12-803547-4.00001-X"},{"key":"ref_77","first-page":"209","article-title":"Durvalumab: An investigational anti-PD-L1 monoclonal antibody for the treatment of orothelial carcinoma","volume":"12","author":"Faiena","year":"2018","journal-title":"Drug Des. Dev."},{"key":"ref_78","unstructured":"US National Library of Medicine (2022, March 29). Phase 2 Study of Durvalumab (MEDI4736) in Patients with Glioblastoma, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT02336165."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1080\/21645515.2020.1782692","article-title":"PD-1\/PD-L1 immune checkpoint inhibitors in glioblastoma: Clinical studies, challenges and potential","volume":"17","author":"Yang","year":"2021","journal-title":"Hum. Vaccin Immunother."},{"key":"ref_80","first-page":"157","article-title":"DNA repair mechanisms in cancer development and therapy","volume":"6","author":"Torngovnick","year":"2015","journal-title":"Front. Genet."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"vi193","DOI":"10.1093\/neuonc\/noab196.765","article-title":"Design and initiation of pivotal studies for Berubicin, a novel potent topoisomerase II poison for the treatment of recurrent glioblastoma multiforme (GBM)","volume":"23","author":"Silberman","year":"2021","journal-title":"Neuro-Oncol."},{"key":"ref_82","first-page":"1031","article-title":"Doxorubicin: An overview of anticancer and chemoresistance mechanisms","volume":"3","author":"Micaleff","year":"2020","journal-title":"Ann. Clin. Toxicol."},{"key":"ref_83","first-page":"B101","article-title":"Phase I clinical pharmacokinetics of RTA744 (Berubicin (B)), a blood-brain barrier penetrating anthracycline active against high grade glioma, and evaluation of its 12-hydroxy metabolite, berubicinol (B-ol)","volume":"6","author":"Kazerooni","year":"2007","journal-title":"Mol. Cancer"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1007\/s10637-019-00744-0","article-title":"Population pharmacokinetic analysis of AR-67, a lactone stable camptothecin analogue in cancer patients with solid tumors","volume":"37","author":"Tang","year":"2019","journal-title":"Investig. New Drugs"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"vi22","DOI":"10.1093\/neuonc\/noz175.082","article-title":"ACTR40. Phase 2 safety and efficacy of AR-67 (7-T-butyldimethylsiltyl-10-hydroxycamptothecin) in patients with recurrent glioblastoma multiforme (GBM) or gliosarcoma","volume":"21","author":"Kumthekar","year":"2019","journal-title":"Neuro-Oncology"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s40265-021-01541-x","article-title":"Fuzuloparib: First approval","volume":"81","author":"Lee","year":"2021","journal-title":"Drugs"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"a026831","DOI":"10.1101\/cshperspect.a026831","article-title":"HDACs and HDAC inhibitors in cancer development","volume":"6","author":"Li","year":"2016","journal-title":"Cold Spring Harb Perspect. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S1359-6446(05)03691-3","article-title":"Chromatin control and cancer-drug discovery: Realizing the promise","volume":"11","author":"Inche","year":"2006","journal-title":"Drug Discov. Today"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1369\/0022155413506582","article-title":"Histone deacetylases: A saga of perturbed acetylation homeostasis in cancer","volume":"62","author":"Parbin","year":"2014","journal-title":"J. Histochem. Cytochem."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.2217\/fon.15.22","article-title":"Molecular targets in glioblastoma","volume":"11","author":"Zorzan","year":"2015","journal-title":"Future Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"18577","DOI":"10.18632\/oncotarget.14612","article-title":"Advances in epigenetic glioblastoma therapy","volume":"8","author":"Lee","year":"2017","journal-title":"Oncotarget"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/1091581809352111","article-title":"Nonclinical safety assessment of the histone deactylase inhibitor vorinostat","volume":"29","author":"Kerr","year":"2010","journal-title":"Int. J. Toxicol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1634\/theoncologist.12-10-1247","article-title":"FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma","volume":"12","author":"Mann","year":"2007","journal-title":"Oncologist"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"6148","DOI":"10.1158\/1078-0432.CCR-09-1039","article-title":"Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks","volume":"15","author":"Palmieri","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1200\/JCO.2008.19.0694","article-title":"Phase II trial of vorinostat in recurrent glioblastoma multiforme: A north Central Cancer Treatment Group study","volume":"27","author":"Galanis","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s11060-017-2724-1","article-title":"Phase I\/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas","volume":"137","author":"Peters","year":"2018","journal-title":"J. Neurooncol."}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/10\/5\/1001\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:01:24Z","timestamp":1760137284000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/10\/5\/1001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,26]]},"references-count":96,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["biomedicines10051001"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines10051001","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,26]]}}}